These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 15019216

  • 1. Treatment efficacy of the lead RNAIII-inhibiting peptide YSPWTNF-NH2 in acquired Staphylococcus aureus sepsis: a histopathological assessment.
    Ribeiro PD, Ribeiro OD, Marcolan AM, Medina-Acosta E.
    Peptides; 2003 Nov; 24(11):1829-36. PubMed ID: 15019216
    [Abstract] [Full Text] [Related]

  • 2. RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis.
    Giacometti A, Cirioni O, Ghiselli R, Dell'Acqua G, Orlando F, D'Amato G, Mocchegiani F, Silvestri C, Del Prete MS, Rocchi M, Balaban N, Saba V, Scalise G.
    Peptides; 2005 Feb; 26(2):169-75. PubMed ID: 15629527
    [Abstract] [Full Text] [Related]

  • 3. RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis.
    Ghiselli R, Giacometti A, Cirioni O, Dell'Acqua G, Bergnach C, Orlando F, Mocchegiani F, Silvestri C, Skerlavaj B, Licci A, Balaban N, Zanetti M, Scalise G, Saba V.
    Shock; 2006 Sep; 26(3):296-301. PubMed ID: 16912656
    [Abstract] [Full Text] [Related]

  • 4. RIP-V improves murine survival in a sepsis model by down-regulating RNAIII expression and α-hemolysin release of methicillin-resistant Staphylococcus aureus.
    Ma B, Zhou Y, Li M, Yu Q, Xue X, Li Z, Da F, Hou Z, Luo X.
    Pharmazie; 2015 Feb; 70(2):81-7. PubMed ID: 25997246
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis.
    Gov Y, Bitler A, Dell'Acqua G, Torres JV, Balaban N.
    Peptides; 2001 Oct; 22(10):1609-20. PubMed ID: 11587789
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. RNAIII-inhibiting-peptide-loaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm formation.
    Anguita-Alonso P, Giacometti A, Cirioni O, Ghiselli R, Orlando F, Saba V, Scalise G, Sevo M, Tuzova M, Patel R, Balaban N.
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2594-6. PubMed ID: 17116671
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococcal sepsis.
    Cirioni O, Ghiselli R, Orlando F, Silvestri C, De Luca S, Salzano AM, Mocchegiani F, Saba V, Scalise G, Scaloni A, Giacometti A.
    Crit Care Med; 2008 Sep; 36(9):2629-33. PubMed ID: 18679116
    [Abstract] [Full Text] [Related]

  • 14. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
    Balaban N, Cirioni O, Giacometti A, Ghiselli R, Braunstein JB, Silvestri C, Mocchegiani F, Saba V, Scalise G.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2226-9. PubMed ID: 17371825
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci.
    Domenico P, Gurzenda E, Giacometti A, Cirioni O, Ghiselli R, Orlando F, Korem M, Saba V, Scalise G, Balaban N.
    Peptides; 2004 Dec; 25(12):2047-53. PubMed ID: 15572191
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. RNAIII Inhibiting Peptide (RIP) and Derivatives as Potential Tools for the Treatment of S. aureus Biofilm Infections.
    Ciulla M, Di Stefano A, Marinelli L, Cacciatore I, Di Biase G.
    Curr Top Med Chem; 2018 Dec; 18(24):2068-2079. PubMed ID: 30345922
    [Abstract] [Full Text] [Related]

  • 19. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus.
    Balaban N, Goldkorn T, Nhan RT, Dang LB, Scott S, Ridgley RM, Rasooly A, Wright SC, Larrick JW, Rasooly R, Carlson JR.
    Science; 1998 Apr 17; 280(5362):438-40. PubMed ID: 9545222
    [Abstract] [Full Text] [Related]

  • 20. Effects of toxin production in a murine model of Staphylococcus aureus keratitis.
    Girgis DO, Sloop GD, Reed JM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2005 Jun 17; 46(6):2064-70. PubMed ID: 15914624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.